Which leads me to the new indications Neuren is developing. To me it looks as if they are carving out the group of indications to use for the platform in order to maximise value in a takeover. If they complete studies and present them to the joint steering committee, and Acadia has no interest or competing studies relating to these indications, Neuren potentially could have up to 10+ indications whereby they could sell the company for a handsome price regardless of the restrictions in the agreement.
Yes, by increasing the number of NNZ-2591 indications under development, Neuren keeps adding value.
But no, Neuren does not have to seek the approval of Acadia /the JSC with respect to any new indications of NNZ-2591.
Furthermore, none of the preclinical work it has completed to date specific to further NNZ-2591 indications has to be shared with Acadia/the JSC because it’s not yet publicly disclosed (Ref: 5.6 (b) (iv)). Hence, while we don’t know what further indications Neuren is pursuing, nor will Acadia.
Even once these new indications are disclosed, Neuren is only obliged to share with Acadia information that is non-indication specific and that relates to safety, tolerability and CMC.
On the other hand, Acadia does have to share with Neuren/the JSC any proposal to develop trofinetide outside of Rett syndrome or Fragile-X syndrome. ACADIA must inform and seek the approval of the JSC (Ref: 6.2 (a))
NEU Price at posting:
$21.27 Sentiment: Hold Disclosure: Held
(20min delay)